Braidwell LP Buys Shares of 515,726 Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Braidwell LP acquired a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 515,726 shares of the company’s stock, valued at approximately $12,640,000. Braidwell LP owned approximately 0.43% of Oruka Therapeutics at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Great Point Partners LLC bought a new position in shares of Oruka Therapeutics in the third quarter worth about $12,614,000. The Manufacturers Life Insurance Company acquired a new position in Oruka Therapeutics during the 3rd quarter worth approximately $1,037,000. Finally, FMR LLC bought a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $114,763,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $20.26 on Friday. The stock’s 50-day moving average is $25.67. Oruka Therapeutics, Inc. has a 12 month low of $18.20 and a 12 month high of $53.88.

Analysts Set New Price Targets

A number of analysts have weighed in on ORKA shares. Lifesci Capital started coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set an “outperform” rating and a $41.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Monday. Stifel Nicolaus began coverage on Oruka Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $49.00 target price for the company. TD Cowen initiated coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set a “buy” rating on the stock. Finally, Leerink Partners assumed coverage on Oruka Therapeutics in a research note on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Oruka Therapeutics presently has an average rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.